CN105188742A - Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途 - Google Patents

Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途 Download PDF

Info

Publication number
CN105188742A
CN105188742A CN201480026267.6A CN201480026267A CN105188742A CN 105188742 A CN105188742 A CN 105188742A CN 201480026267 A CN201480026267 A CN 201480026267A CN 105188742 A CN105188742 A CN 105188742A
Authority
CN
China
Prior art keywords
egfr
biomarker
patient
tumor
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480026267.6A
Other languages
English (en)
Chinese (zh)
Inventor
杨劼
Y·陈
H·Q·李
蔡杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Xinwei Biotechnology Co ltd
Crown Bioscience Inc Taicang
Original Assignee
Crown Bioscience Inc Taicang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Bioscience Inc Taicang filed Critical Crown Bioscience Inc Taicang
Priority to CN201480026267.6A priority Critical patent/CN105188742A/zh
Publication of CN105188742A publication Critical patent/CN105188742A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
CN201480026267.6A 2013-03-14 2014-03-14 Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途 Pending CN105188742A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201480026267.6A CN105188742A (zh) 2013-03-14 2014-03-14 Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2013/072638 2013-03-14
PCT/CN2013/072638 WO2014139131A1 (en) 2013-03-14 2013-03-14 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
CN201480026267.6A CN105188742A (zh) 2013-03-14 2014-03-14 Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途
PCT/US2014/028714 WO2014153018A1 (en) 2013-03-14 2014-03-14 Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents

Publications (1)

Publication Number Publication Date
CN105188742A true CN105188742A (zh) 2015-12-23

Family

ID=51535817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480026267.6A Pending CN105188742A (zh) 2013-03-14 2014-03-14 Egfr生物标志物用于利用抗egfr试剂治疗胃癌的用途

Country Status (4)

Country Link
US (1) US10442862B2 (enExample)
JP (2) JP6675300B2 (enExample)
CN (1) CN105188742A (enExample)
WO (2) WO2014139131A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106884018A (zh) * 2017-01-19 2017-06-23 江苏大学 一种检测致癌蛋白表皮生长因子受体的试剂及试剂盒
CN109722478A (zh) * 2017-10-31 2019-05-07 嘉兴雅康博医学检验所有限公司 用于检测egfr基因2312-2313位突变的引物、探针及试剂盒
US11459618B2 (en) 2017-03-29 2022-10-04 Crown Bioscience, Inc. (Taicang) System and method for determining Cetuximab sensitivity on gastric cancer

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents
US10484156B2 (en) * 2016-11-16 2019-11-19 Qualcomm Incorporated Search space associated with physical downlink control channel based on channel quality indicators
JP7396902B2 (ja) * 2017-06-06 2023-12-12 ユニバーシティ オブ メリーランド，カレッジ パーク 転移検出のために単一細胞の機械的フェノタイピングを行う分析
CN107582993A (zh) * 2017-11-10 2018-01-16 兰志英 一种治疗胃癌的药物及其制备方法
CN113164480B (zh) * 2018-11-14 2023-11-28 学校法人金泽医科大学 用于治疗弥漫性胃癌的药物组合物
CN115197320A (zh) * 2021-04-07 2022-10-18 中美冠科生物技术（太仓）有限公司 新型抗cd4抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5422120B2 (ja) * 2004-05-27 2014-02-19 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
WO2007076923A1 (en) 2006-01-04 2007-07-12 Merck Patent Gmbh Combination therapy using anti-egfr and anti-her2 antibodies
US20090017050A1 (en) * 2007-07-13 2009-01-15 Ventana Medical Systems, Inc. Egfr antigen-binding molecules and uses thereof
EP3216874A1 (en) * 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Methods for stratifying and annotating cancer drug treatment options
EP2711704B1 (en) * 2011-05-16 2017-06-28 Taiho Pharmaceutical Co., Ltd. Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
WO2014139131A1 (en) 2013-03-14 2014-09-18 Crown Bioscience, Inc. Use of egfr biomarkers for the treatment of gastric cancer with anti-egfr agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
MASAYASU HARA等: "Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity", 《CANCER SCI》 *
TOMISLAV DRAGOVICH等: "Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers:An Evolving Concept", 《JOURNAL OF ONCOLOGY》 *
ZHIYONG LIANG等: "Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients", 《BMC CANCER》 *
刘伟等: "EGFR在中国胃癌患者中的表达及其临床意义", 《世界华人消化杂志》 *
米登海登: "胃癌分子靶向治疗", 《国际肿瘤学杂志》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106884018A (zh) * 2017-01-19 2017-06-23 江苏大学 一种检测致癌蛋白表皮生长因子受体的试剂及试剂盒
CN106884018B (zh) * 2017-01-19 2021-03-23 江苏大学 一种检测致癌蛋白表皮生长因子受体的试剂及试剂盒
US11459618B2 (en) 2017-03-29 2022-10-04 Crown Bioscience, Inc. (Taicang) System and method for determining Cetuximab sensitivity on gastric cancer
TWI859118B (zh) * 2017-03-29 2024-10-21 大陸商中美冠科生物技術（太倉）有限公司 測定對胃癌之西妥昔單抗（ｃｅｔｕｘｉｍａｂ）敏感性的系統及方法
CN109722478A (zh) * 2017-10-31 2019-05-07 嘉兴雅康博医学检验所有限公司 用于检测egfr基因2312-2313位突变的引物、探针及试剂盒

Also Published As

Publication number Publication date
US20160024216A1 (en) 2016-01-28
US10442862B2 (en) 2019-10-15
WO2014153018A1 (en) 2014-09-25
WO2014139131A1 (en) 2014-09-18
JP2016515141A (ja) 2016-05-26
JP6675300B2 (ja) 2020-04-01
JP2020040959A (ja) 2020-03-19

Similar Documents

Publication Publication Date Title
JP6675300B2 (ja) 抗ｅｇｆｒ薬を用いた胃癌の処置のための、ｅｇｆｒバイオマーカーの使用
CA2891609C (en) Method for the prognosis and treatment of cancer metastasis
JP5926487B2 (ja) ＥｒｂＢ療法に耐性である癌を治療するための方法
RU2706968C2 (ru) Диагностические способы и композиции для лечения глиобластомы
JP2018508183A (ja) 化学療法耐性癌を治療及び診断する組成物及び方法
US8980557B2 (en) Marker for determination of sensitivity to triplet combination anti-cancer agent
AU2014229505A1 (en) Method for the prognosis and treatment of cancer metastasis
JP2019518426A (ja) がんの診断及び治療方法
JP2017523776A (ja) 膠芽腫の診断方法及びその治療用組成物
WO2010040083A2 (en) Gene expression predictors of chemoresistance
JP2019527037A (ja) がんのための診断及び治療方法
US20210010084A1 (en) Biomarker for her2-positive cancer and anti-her2 therapy and applications thereof
CN105407913A (zh) 用于鉴定可用抗egfr药物治疗的食管癌患者的生物标志物
US20140105893A1 (en) Method for selecting chemotherapy for gastric cancer patient using combination drug of tegafur, gimeracil and oteracil potassium and egfr inhibitor
EP2494070A2 (en) Methods for treating cancer in patients having igf-1r inhibitor resistance
JP2024542977A (ja) 液体生検によって検出される新規キナーゼ融合
WO2023282749A1 (en) Gene classifier for spatial immune phenotypes of cancer
US12351878B2 (en) Identification of HER2 mutations in lung cancer and methods of treatment
US8609354B2 (en) Method for selecting patients for treatment with an EGFR inhibitor
AU2011222867A1 (en) Method for selecting patients for treatment with an EGFR inhibitor
KR20160003646A (ko) 항-egfr 제제에 의해 위암을 치료하기 위한 egfr 바이오마커의 용도
HK1230250A1 (en) Diagnostic methods and compositions for treatment of glioblastoma
HK1182449A (en) Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
HK1206431B (en) Method for the prognosis and treatment of cancer metastasis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20170928

Address after: 215400 Jiangsu Taicang Suzhou Economic Development Zone Beijing Taicang West Road 6 science and Technology Pioneering Park

Applicant after: CROWN BIOSCIENCE Inc. (TAICANG)

Applicant after: Zhejiang Xinwei Biotechnology Co.,Ltd.

Address before: 215400 Jiangsu Taicang Suzhou Economic Development Zone Beijing West Road 6 science and Technology Pioneer Park

Applicant before: CROWN BIOSCIENCE Inc. (TAICANG)

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20151223